Elusys' anthrax product approaches market
This article was originally published in Scrip
Executive Summary
Private US biotech firm Elusys Therapeutics has proved its antitoxin inhalational anthrax treatment obiltoxaximab in three Phase III studies, paving the way for a BLA filing, the company says.